Analyst Ratings For Diurnal Group PLC (LON:DNL)
Today, Numis Securities Ltd reiterated its Buy rating on Diurnal Group PLC (LON:DNL) with a price target of GBX 187.
There are 1 buy rating on the stock.
The current consensus rating on Diurnal Group PLC (LON:DNL) is Buy (Score: 3.00) with a consensus target price of GBX 187 per share, a potential .
Some recent analyst ratings include
- 3/2/2017-Numis Securities Ltd Reiterated Rating of Buy.
About Diurnal Group PLC (LON:DNL)
Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism. The Company’s products are under various clinical trials, including Chronocort, which is in Phase III clinical trial; Infacort, which is in Phase III clinical trial, and Native Oral Testosterone, which is in Phase I clinical trial.
Recent Trading Activity for Diurnal Group PLC (LON:DNL)
Shares of Diurnal Group PLC closed the previous trading session at 137.98 up +4.48 3.35% with 0 shares trading hands.
